Ipv-Boostrix

Aluminium Phosphate, Diphtheria Toxoid Adsorbed On Aluminium Hydroxide, the active ingredient in Ipv-Boostrix, is a vaccine presented as an injectable vaccine for intramuscular use. The formulation contains aluminium salts as adjuvants to boost immune response and protects against diphtheria, tetanus, pertussis and poliomyelitis in children and adults.

GNH USA supplies Ipv-Boostrix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards.

Ipv-Boostrix is used in immunization programs targeting bacterial and viral diseases that affect the respiratory and nervous systems.

- Diphtheria: induces protective antibodies against diphtheria toxin, preventing disease. - Tetanus: stimulates immunity to tetanus toxin, reducing risk of tetanus infection. - Pertussis: generates antibodies that limit Bordetella pertussis colonisation and cough severity. - Poliomyelitis: elicits neutralising antibodies that block poliovirus replication and paralysis.

Ipv-Boostrix may cause a range of post‑vaccination reactions, most of which are mild and self‑limiting.

Common Side Effects: - Injection site pain: soreness at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: mild temperature rise within 24‑48 hours. - Headache: transient headache after vaccination. - Fatigue: temporary tiredness or malaise. - Muscle aches: mild myalgia around the injection area.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: rare neurologic events post‑vaccination. - Guillain‑Barré syndrome: extremely rare autoimmune neuropathy. - Severe allergic reaction: urticaria, angioedema, or bronchospasm. - High‑grade fever: persistent fever above 39 °C. - Thrombocytopenia: rare drop in platelet count.

Before administering Ipv-Boostrix, healthcare professionals should observe the following precautions.

- Allergy screening: avoid use in individuals with known hypersensitivity to any vaccine component. - Acute illness: postpone vaccination if the patient has a moderate or severe febrile illness. - Immunocompromised status: consult a specialist before vaccinating patients with weakened immune systems. - Post‑injection monitoring: observe the recipient for at least 15 minutes for immediate adverse reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ipv-Boostrix can interact with certain medical products that may alter its immunogenicity or safety profile.

Major Interactions (Avoid): - Immunoglobulin therapy: may diminish vaccine efficacy; avoid simultaneous administration. - Blood products (e.g., plasma): can interfere with immune response; schedule at least 24 hours apart.

Moderate Interactions (Monitor Closely): - Other inactivated vaccines given at the same visit: monitor for additive local reactions. - Antipyretics (acetaminophen, ibuprofen): may mask fever; assess symptom severity. - Systemic corticosteroids: may reduce antibody production; consider timing of dose. - Live vaccines administered within 4 weeks: monitor for potential immune interference.